Innate Pharma announces Phase II results from monalizumab and cetuximab combination in head and neck cancer at the ESMO 2018 Congress
Innate Pharma announces data presentations on monalizumab at the European Society for Medical Oncology annual meeting 2018
Innate Pharma reports IPH4102 results in advanced Cutaneous T Cell Lymphoma (CTCL)
Innate Pharma reports first half 2018 financial results and business update
Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi®) in solid tumors
Innate Pharma announces data presentations at upcoming scientific meetings
Innate pharma announces a change to its 2018 financial calendar
Clinical data from ongoing Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) in colorectal cancer patients presented at 2018 ASCO annual meeting
Outcome of Annual General Meeting of May 29, 2018
Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
